Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
Silvia Novello;
2018-01-01
Abstract
Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer.pdf
Open Access dal 26/03/2019
Tipo di file:
PDF EDITORIALE
Dimensione
187.52 kB
Formato
Adobe PDF
|
187.52 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
